Cargando…
METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation
The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3....
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050319/ https://www.ncbi.nlm.nih.gov/pubmed/36977668 http://dx.doi.org/10.1038/s41419-023-05715-1 |
_version_ | 1785014623810879488 |
---|---|
author | Lin, Chengjie Li, Ting Wang, Yan Lai, Shihui Huang, Yue Guo, Zhenyun Zhang, Xiang Weng, Shangeng |
author_facet | Lin, Chengjie Li, Ting Wang, Yan Lai, Shihui Huang, Yue Guo, Zhenyun Zhang, Xiang Weng, Shangeng |
author_sort | Lin, Chengjie |
collection | PubMed |
description | The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3. In situ fluorescence hybridization was conducted to localize the cellular distribution of METTL3 and DEAD-box helicase 23 (DDX23). CCK8, colony formation, EDU incorporation, TUNEL, wound healing and Transwell assays were carried out accordingly to study the viability, proliferation, apoptosis, and mobility of cells under different treatments in vitro. Xenograft and animal lung metastasis experiments were also conducted to study the functional role of METTL3 or DDX23 on tumor growth and lung metastasis in vivo. MeRIP-qPCR and bioinformatical analyses were used to obtain the potential direct targets of METTL3. It was shown that m6A methyltransferase METTL3 was upregulated in PDAC tissues with gemcitabine resistance, and its knockdown sensitized pancreatic cancer cells to chemotherapy. Furthermore, silencing METTL3 remarkably reduced pancreatic cancer cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, validation experiments confirmed that DDX23 mRNA was a direct target of METTL3 in YTHDF1-dependent manner. Additionally, DDX23 silence resulted in the suppression of pancreatic cancer cell malignancy and PIAK/Akt signaling inactivation. Strikingly, rescuse experiments demonstrated the inhibitive effects of METTL3 silence on cell phenotypes and gemcitabine resistance were partially reversed by forcibly expressed DDX23. In summary, METTL3 promotes PDAC progression and gemcitabine resistance by modifying DDX23 mRNA m6A methylation and enhancing PI3K/Akt signaling activation. Our findings establish a potential tumor promotive and chemo-resistant role for METTL3/DDX23 axis in PDAC. |
format | Online Article Text |
id | pubmed-10050319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-100503192023-03-30 METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation Lin, Chengjie Li, Ting Wang, Yan Lai, Shihui Huang, Yue Guo, Zhenyun Zhang, Xiang Weng, Shangeng Cell Death Dis Article The aim of the present study was to clarify the mechanism of how METTL3 regulated pancreatic ductal adenocarcinoma (PDAC) progression by m6A modification of its downstream target mRNA and signaling pathway. Immunoblotting and qRT-PCR assays was employed to determine the expression levels of METTL3. In situ fluorescence hybridization was conducted to localize the cellular distribution of METTL3 and DEAD-box helicase 23 (DDX23). CCK8, colony formation, EDU incorporation, TUNEL, wound healing and Transwell assays were carried out accordingly to study the viability, proliferation, apoptosis, and mobility of cells under different treatments in vitro. Xenograft and animal lung metastasis experiments were also conducted to study the functional role of METTL3 or DDX23 on tumor growth and lung metastasis in vivo. MeRIP-qPCR and bioinformatical analyses were used to obtain the potential direct targets of METTL3. It was shown that m6A methyltransferase METTL3 was upregulated in PDAC tissues with gemcitabine resistance, and its knockdown sensitized pancreatic cancer cells to chemotherapy. Furthermore, silencing METTL3 remarkably reduced pancreatic cancer cell proliferation, migration, and invasion both in vitro and in vivo. Mechanistically, validation experiments confirmed that DDX23 mRNA was a direct target of METTL3 in YTHDF1-dependent manner. Additionally, DDX23 silence resulted in the suppression of pancreatic cancer cell malignancy and PIAK/Akt signaling inactivation. Strikingly, rescuse experiments demonstrated the inhibitive effects of METTL3 silence on cell phenotypes and gemcitabine resistance were partially reversed by forcibly expressed DDX23. In summary, METTL3 promotes PDAC progression and gemcitabine resistance by modifying DDX23 mRNA m6A methylation and enhancing PI3K/Akt signaling activation. Our findings establish a potential tumor promotive and chemo-resistant role for METTL3/DDX23 axis in PDAC. Nature Publishing Group UK 2023-03-28 /pmc/articles/PMC10050319/ /pubmed/36977668 http://dx.doi.org/10.1038/s41419-023-05715-1 Text en © The Author(s) 2023, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Lin, Chengjie Li, Ting Wang, Yan Lai, Shihui Huang, Yue Guo, Zhenyun Zhang, Xiang Weng, Shangeng METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title | METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title_full | METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title_fullStr | METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title_full_unstemmed | METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title_short | METTL3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying DDX23 mRNA N6 adenosine methylation |
title_sort | mettl3 enhances pancreatic ductal adenocarcinoma progression and gemcitabine resistance through modifying ddx23 mrna n6 adenosine methylation |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10050319/ https://www.ncbi.nlm.nih.gov/pubmed/36977668 http://dx.doi.org/10.1038/s41419-023-05715-1 |
work_keys_str_mv | AT linchengjie mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT liting mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT wangyan mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT laishihui mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT huangyue mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT guozhenyun mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT zhangxiang mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation AT wengshangeng mettl3enhancespancreaticductaladenocarcinomaprogressionandgemcitabineresistancethroughmodifyingddx23mrnan6adenosinemethylation |